Liver Cancer Drug Market Size, Share and Trends 2025 to 2034
Liver Cancer Drug Market (By Drug Type: Targeted Therapy, Immunotherapy, Chemotherapy, Combination Therapy; By Mechanism of Action: Tyrosine Kinase Inhibitors, Checkpoint Inhibitors, Monoclonal Antibodies, Anti-Angiogenic Agents; By Formulation: Oral, Injectable; By Application: Advanced Liver Cancer, Early-Stage Liver Cancer, Post-Surgery Adjuvant Therapy; By End-User: Hospitals, Specialty Oncology Clinics, Cancer Research Institutes, Homecare/Palliative Care) - Global Industry Analysis, Size, Trends, Leading Companies, Regional Outlook, and Forecast 2025 to 2034
Get a Sample
Table Of Content
What is the Liver Cancer Drug Market Size?
The global liver cancer drug market size accounted for USD 4.39 billion in 2025 and is predicted to increase from USD 5.19 billion in 2026 to approximately USD 19.65 billion by 2034, expanding at a CAGR of 18.11% from 2025 to 2034. The global liver cancer drug market is experiencing significant growth, driven by the increased liver cancer prevalence and advancements in treatment potions like antiviral and immunosuppressive therapies.
Market Highlights
- North America dominated the global liver cancer drug market with the largest share of 37.8% in 2024.
- The Asia Pacific is expected to grow at the highest CAGR of 12.4% from 2025 to 2034.
- By drug type, the targeted therapy segment contributed the largest market share of 41.8% in 2024.
- By drug type, the immunotherapy segment is growing at a notable CAGR of 11.6% from 2025 to 2034.
- By mechanism of action, the tyrosine kinase inhibitors segment led the market while holding the largest share of 46.4% in 2024.
- By mechanism of action, the checkpoint inhibitors segment is expected to grow at a 11.8% CAGR between 2025 and 2034.
- By formulation, the oral segment led the market while holding the largest share of 48.4% in 2024.
- By formulation, the injectable segment is growing at a strong CAGR of 11.7% between 2025 and 2034.
- By application, the advanced liver cancer segment led the market while holding the largest share of 51.5% in 2024.
- By application, the early-stage liver cancer segment is expected to grow at a 12.2% CAGR between 2025 and 2034.
- By end-user, the hospitals segment led the market while holding the largest share of 45.4% in 2024.
- By end-user, the specialty oncology clinics segment is expected to grow at a 12.0% CAGR between 2025 and 2034.
What is Liver Cancer Drug?
The liver cancer drug market is experiencing significant growth, driven by the rising global incidence of liver cancer, advancements in therapeutics such as immunotherapies and targeted treatments, and increased R&D investment. The market encompasses pharmaceutical therapies for hepatocellular carcinoma (HCC), the most common form of liver cancer, as well as other hepatic malignancies. Key treatment modalities include targeted therapies, immunotherapies, chemotherapy , and combination regimens that aim to inhibit tumor progression and enhance patient survival outcomes.
Growth is further supported by the increasing prevalence of liver cancer, heightened awareness of early diagnosis, and the continuous development of novel agents such as immune checkpoint inhibitors and molecularly targeted drugs. Additionally, the adoption of personalized medicine is enabling more tailored and effective treatment strategies worldwide. Rising global awareness about liver cancer is amplifying the demand for early detection and therapeutic intervention.
- In October 2025, the Mayo Clinic became the first institution to administer an investigational radioactive medicine for a patient with hepatocellular carcinoma. This targeted radiopharmaceutical theragnostic (RPT) therapy is designed to home in on glypican-3 (GPC3), a protein overexpressed in HCC, representing a promising frontier in precision oncology .
Key Technological Shift in the Liver Cancer Drug Industry?
The liver cancer drug industry is undergoing a transformative technological paradigm shift, characterized by a robust pivot towards precision medicine and targeted therapeutic modalities. The rising demand for targeted therapies, such as sorafenib and Lenvatinib, centers on inhibiting key molecular pathways that drive tumor proliferation. Furthermore, the strategic integration of targeted agents with immunotherapies or chemotherapeutic regimens is enhancing therapeutic efficacy and overcoming tumor resistance mechanisms. This evolution is underpinned by escalating investments in R&D that facilitate adaptive clinical trials , enabling the customization of treatment protocols tailored to individual patient molecular profiles.
Simultaneously, the growing deployment of artificial intelligence (AI) technologies in drug discovery is catalyzing the identification of novel therapeutic targets and optimizing drug development pipelines, thereby accelerating the introduction of innovative liver cancer therapies. Industry frontrunners, including Roche, Bristol-Myers Squibb, Bayer AG, Merck & Co., Exelixis, BeiGene, and Gilead Sciences, are spearheading this technological transition, investing heavily in advanced platforms such as targeted nanoparticle delivery systems, immuno- oncology , organ-on-a-chip models, gene therapy , AI-driven radiomics, and multi-modal combination therapies. Emerging collaborations, exemplified by AI-enabled drug discovery partnerships like Cellares' integrated manufacturing platform, further exemplify the dynamic innovation shaping the liver cancer drug landscape.
Liver Cancer Drug Market Outlook
[[market_outlook]]
Market Scope
| Report Coverage | Details |
| Market Size in 2025 | USD 4.39 Billion |
| Market Size in 2026 | USD 5.19 Billion |
| Market Size by 2034 | USD 19.65 Billion |
| Market Growth Rate from 2025 to 2034 | CAGR of 18.11% |
| Dominating Region | North America |
| Fastest Growing Region | Asia Pacific |
| Base Year | 2024 |
| Forecast Period | 2025 to 2034 |
| Segments Covered | Drug Type, Mechanism of Action, Formulation, Application, End-User, and Region |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Liver Cancer Drug Market Segment Insights
[[segment_insights]]
Liver Cancer Drug MarketRegional Insights
[[regional_insights]]
Liver Cancer Drug Market Value Chain
[[value_chain]]
Liver Cancer Drug Market Companies
Tier I: Market Leaders
These companies dominate the liver cancer drug market, collectively accounting for over 40% of the global revenue.
| Company | Key Offerings |
| Bayer AG | Nexavar (sorafenib), Stivarga (regorafenib) |
| Bristol Myers Squibb | Opdivo (nivolumab), Yervoy (ipilimumab) combined with Opdivo |
| Exelixis, Inc | Cabometyx (cabozantinib) |
| Merck KGaA | Bavencio (avelumab) |
| Eisai Co., Ltd. | Lenvima (lenvatinib) |
Tier II: Established Players
These companies have significant oncology portfolios and are expanding their market presence.
| Company | Key Offerings |
| Exelixis, Inc. | Cabometyx (cabozantinib) |
| Eli Lilly and Co. | Verzenio (abemaciclib), Alimta (pemetrexed) |
| GlaxoSmithKline (GSK) | Zejula (niraparib) |
| Pfizer Inc. | Ibrance (palbociclib), Xalkori (crizotinib) |
| AstraZeneca | Tagrisso (osimertinib), Lynparza (olaparib) |
Tier III: Emerging and Niche Players
These companies have smaller oncology portfolios or operate in specific regional markets.
| Company | Key Offerings |
| Gilead Sciences | Yescarta (axicabtagene ciloleucel), Trodelvy (sacituzumab govitecan-hziy) |
| Sanofi | Blincyto (blinatumomab), Libtayo (cemiplimab) |
| BeiGene | Brukinsa (zanubrutinib), tislelizumab |
| Daiichi Sankyo | Enhertu (fam-trastuzumab deruxtecan-nxki), U3-1402 |
| Bayer | Stivarga (regorafenib), Nexavar (sorafenib) |
| GSK | Zejula (niraparib) |
| Teva Pharmaceuticals | Copaxone (glatiramer acetate) (not oncology-focused) |
Recent Developments
- In August 2025, the study on the ImmunoTACE trial was published in Clinical Cancer Research, an academic journals, found enhanced progression-free survival (PFS) for patient with hepatocellular carcinoma (HCC). According to the study, patients who received the cell-based vaccine along with standard therapy saw a longer period of progression-free survival than patients who received standard therapy alone.(Source: https://ecancer.org )
- In June 2025, UPMC Central PA Surgical Oncology introduced a specialized treatment, hepatic arterial infusion (HAI) pump therapy for patients with either metastatic cancer to the liver or cancers emerging in the liver. HAI therapy is able to more precisely target liver tumors to improve patient eligibility for curative-intent surgery and overall survival of the patients. (Source: https://www.upmc.com )
- In April 2025, the combination of nivolumab and ipilimumab received approval from the U.S. Food and Drug Administration as a prior treatment for adults with metastatic hepatocellular carcinoma. U.S. FDA has approved this therapy, due to positive results of the Phase 3 CheckMte 9DW trial, with significant improvement in survival with the immunotherapy-based combinations.(Source: https://acsjournals.onlinelibrary.wiley.com )
Exclusive Analysis
The global liver cancer drug market is poised for substantial expansion, underpinned by several pivotal factors, including the escalating incidence of hepatocellular carcinoma (HCC), advancements in therapeutic modalities, and a robust pipeline of investigational agents. The therapeutic landscape is undergoing a significant transformation, shifting from traditional systemic chemotherapies to more targeted and personalized treatment approaches. Immunotherapeutic agents, particularly immune checkpoint inhibitors, have emerged as critical components in the management of HCC, offering enhanced survival outcomes and improved patient prognoses. The integration of combination therapies, such as the pairing of checkpoint inhibitors with vascular endothelial growth factors (VEGF) inhibitors or tyrosine kinase inhibitors (TKIs), is further augmenting the efficacy of treatment regimens.
Geographically, Asia Pacific is experiencing accelerated market growth, driven by a high prevalence of HCC and increasing healthcare infrastructure investments. In 2024, the region accounted for a significant portion of the global market share, with projections indicating continued dominance through 2034.
Strategic collaborations and licensing agreements are becoming increasingly prevalent, as pharmaceutical companies seek to enhance their portfolios and expedite the development of novel therapies. For instance, GSK's acquisition of efimosfermin, a promising agent for steatotic liver disease and metabolic-associated steatohepatitis, underscores the industry's commitment to addressing unmet medical needs within the liver disease spectrum.
In summary, the liver cancer drug market presents a dynamic and rapidly evolving landscape, characterized by significant investment opportunities and a strong pipeline of innovative therapies. Stakeholders within the biopharmaceutical sector are well-positioned to capitalize on these developments, contributing to the advancement of treatment paradigms and the improvement of patient outcomes in liver cancer management.
Liver Cancer Drug MarketSegments Covered in the Report
[[segment_covered]]
For inquiries regarding discounts, bulk purchases, or customization requests, please contact us at sales@precedenceresearch.com
Frequently Asked Questions
Ask For Sample
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
.webp)
sales@precedenceresearch.com
+1 804-441-9344
Schedule a Meeting